ALK signalling primes the DNA damage response sensitizing ALK-driven neuroblastoma to ATR inhibition
Borenäs, M.; Umapathy, G.; Lind, D. E.; Lai, W.-Y.; Guan, J.; Johansson, J.; Jennische, E.; Schmidt, A.; Kurhe, Y. V.; Gabre, J. L.; Aniszewska, A.; Strömberg, A.; Bemark, M.; Hall, M. N.; Van den Eynden, J.; Hallberg, B.; Palmer, R. H.
Show abstract
High-risk neuroblastoma (NB) is a significant clinical challenge. MYCN and ALK, which are often involved in high-risk NB, lead to increased replication stress in cancer cells, suggesting therapeutic strategies. We previously identified an ATR/ALK inhibitor (ATRi/ALKi) combination as such a strategy in two independent genetically modified mouse NB models. Here, we identify an underlying molecular mechanism, in which ALK signalling leads to phosphorylation of ATR and CHK1, supporting an effective DNA damage response. The importance of ALK inhibition is supported by mouse data, in which ATRi monotreatment resulted in a robust initial response, but subsequent relapse, in contrast to a 14-day ALKi/ATRi combination treatment that resulted in a robust and sustained response. Finally, we show that the remarkable response to the 14-day combined ATR/ALK inhibition protocol reflects a robust differentiation response, reprogramming tumour cells to a neuronal/Schwann cell lineage identity. Our results identify a unique ability of ATR inhibition to trigger neuroblastoma differentiation and underscore the importance of further exploring combined ALK/ATR inhibition in NB, particularly in high-risk patient groups with oncogene-induced replication stress.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Inhibition of the YAP-MMB interaction and targeting NEK2 as potential therapeutic strategies for YAP-driven cancers 95%
- Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment 95%
- DARPP-32 promotes ERBB3-mediated resistance to molecular targeted therapy in EGFR-mutated lung adenocarcinoma 94%
Similar papers in this journal
- USP28 enables oncogenic transformation of respiratory cells and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K. 94%
- MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation 94%
- Inhibition of autophagy as a novel therapy for the treatment of neurofibromatosis type 1 tumors 94%
Similar papers in this journal
Similar papers in this journal
- Combination Therapies Targeting Alk-Aberrant Neuroblastoma In Preclinical Models. 95%
- RRAS and RRAS2 mutations are recurrent oncogenic drivers in lung cancer and are sensitive to the pan-RAS inhibitor RMC-6236 94%
- Targeting BET Proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.